PR Newswire Europe - New Long-Term Clinical Studies and Health-Related Quality of Life Data Show Promise of Topamax(R) in Prevention of Migraine Episodes.
Tuesday, October 21st, 2008ATHENS, Greece, September 19 /PRNewswire/ — Results from two large clinical trials demonstrate that patients with frequent migraine who were treated with TOPAMAX(R) (topiramate) for up to 14 months (6 months double blind followed by 8 months open label) had a persistent reduction in the frequency of migraine headaches(1).
Related Results
…
